Related Experiment Videos
Low levels of intraplatelet cGMP in IDDM
J A Amado1, E Salas, M A Botana
1Department of Medicine, Hospital Universitario Marques de Valdecilla, University of Cantabria, Spain.
Objective:
To determine the levels of intraplatelet cGMP, an index of activity of the antiaggregatory nitric oxide pathway, in IDDM patients.
Research Design And Methods:
We measured intraplatelet and plasmatic cGMP levels in 22 IDDM patients and 22 age- and sex-matched control subjects.
Results:
Intraplatelet cGMP levels decreased in the IDDM patients (0.32 +/- 0.16 pmol/10(9) platelets) when compared with the control group (0.52 +/- 0.32 pmol/10(9) platelets), P = 0.032. Plasmatic cGMP levels were not significantly different between groups. Intraplatelet cGMP levels correlated negatively with the duration of the disease (r = -0.43, P < 0.05).
Conclusions:
IDDM patients have lower levels of intraplatelet cGMP, which may be responsible in part for their platelet hyperactivity.